Zeena Salman

2.0k total citations
27 papers, 576 citations indexed

About

Zeena Salman is a scholar working on Genetics, Oncology and Hematology. According to data from OpenAlex, Zeena Salman has authored 27 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Oncology and 7 papers in Hematology. Recurrent topics in Zeena Salman's work include Chronic Lymphocytic Leukemia Research (7 papers), Multiple Myeloma Research and Treatments (5 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Zeena Salman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Multiple Myeloma Research and Treatments (5 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Zeena Salman collaborates with scholars based in United States, Canada and Jordan. Zeena Salman's co-authors include Thorsten Graef, Gregory D. Kirk, Mark D. DeBoer, Jeffrey Matous, Chaim Shustik, Véronique Leblond, Beatrice Mahé, D. Blair Macdonald, Christian Buske and Charles Herbaux and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Zeena Salman

26 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zeena Salman United States 10 304 268 163 158 139 27 576
Anca Prica Canada 14 147 0.5× 234 0.9× 141 0.9× 238 1.5× 119 0.9× 130 609
Thomas E. Lew Australia 16 573 1.9× 428 1.6× 211 1.3× 163 1.0× 219 1.6× 33 880
Tzung‐Chih Tang Taiwan 14 111 0.4× 197 0.7× 216 1.3× 146 0.9× 147 1.1× 33 507
Randy Davis United States 10 385 1.3× 448 1.7× 108 0.7× 128 0.8× 69 0.5× 19 858
Ilaria Nichele Italy 11 209 0.7× 102 0.4× 142 0.9× 64 0.4× 82 0.6× 23 413
Marwan Yared United States 12 73 0.2× 192 0.7× 90 0.6× 176 1.1× 103 0.7× 20 523
Peter Joosten Netherlands 10 110 0.4× 155 0.6× 212 1.3× 227 1.4× 58 0.4× 18 527
Vittorio Meneghini Italy 12 159 0.5× 321 1.2× 107 0.7× 174 1.1× 42 0.3× 21 516
S Gentili Italy 10 345 1.1× 92 0.3× 399 2.4× 139 0.9× 154 1.1× 16 685
Frank T. Ward United States 8 197 0.6× 161 0.6× 84 0.5× 131 0.8× 31 0.2× 13 429

Countries citing papers authored by Zeena Salman

Since Specialization
Citations

This map shows the geographic impact of Zeena Salman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeena Salman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeena Salman more than expected).

Fields of papers citing papers by Zeena Salman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zeena Salman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeena Salman. The network helps show where Zeena Salman may publish in the future.

Co-authorship network of co-authors of Zeena Salman

This figure shows the co-authorship network connecting the top 25 collaborators of Zeena Salman. A scholar is included among the top collaborators of Zeena Salman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeena Salman. Zeena Salman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sultan, Iyad, et al.. (2025). Trends in childhood cancer: Incidence and survival analysis over 45 years of SEER data. PLoS ONE. 20(1). e0314592–e0314592. 5 indexed citations
2.
Rihani, Rawad, Sima Jeha, Zeena Salman, et al.. (2025). Restoring health and hope to displaced Gaza children with malignant disease at a cancer centre in Jordan. Eastern Mediterranean Health Journal. 31(4). 243–249. 1 indexed citations
3.
4.
Salman, Zeena, et al.. (2024). Smoking-Related Disease Impact in the Eastern Mediterranean Region: A Comprehensive Assessment Using Global Burden of Disease Data. Asian Pacific Journal of Cancer Prevention. 25(2). 495–505. 7 indexed citations
5.
6.
7.
Zhou, Yanhong, et al.. (2022). AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials. Pharmaceutical Statistics. 22(2). 300–311. 3 indexed citations
8.
Salman, Zeena, et al.. (2021). Cancer care for children in the Gaza Strip. The Lancet Oncology. 22(12). 1667–1668. 1 indexed citations
9.
Mills, David, et al.. (2021). Implementation of a pediatric early warning score tool in a pediatric oncology Ward in Palestine. BMC Health Services Research. 21(1). 1159–1159. 8 indexed citations
10.
Richardson, Paul G., Akshanth R. Polepally, Monica Motwani, et al.. (2020). A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 136(Supplement 1). 16–17. 3 indexed citations
11.
Chari, Ajai, Robert F. Cornell, Cristina Gasparetto, et al.. (2020). Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological Oncology. 38(3). 353–362. 12 indexed citations
12.
Richardson, Paul G., William Bensinger, Carol Ann Huff, et al.. (2018). Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology. 180(6). 821–830. 30 indexed citations
13.
Chari, Ajai, Sarah M. Larson, Beata Holkova, et al.. (2018). Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia & lymphoma. 59(11). 2588–2594. 20 indexed citations
14.
Dimopoulos, Meletios Α., Alessandra Tedeschi, Judith Trotman, et al.. (2018). Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia. New England Journal of Medicine. 378(25). 2399–2410. 233 indexed citations
15.
Chari, Ajai, Saulius Girnius, Saurabh Chhabra, et al.. (2017). Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 130. 3111–3111. 2 indexed citations
16.
Mills, David, et al.. (2017). Unique Barriers to Care and Outcomes of Pediatric Acute Lymphoblastic Leukemia Treatment in Gaza City, Occupied Palestinian Territory. Journal of Global Oncology. 3(2_suppl). 25s–26s. 1 indexed citations
17.
Salman, Zeena, et al.. (2016). An Intensive Induction Protocol for High Risk Neuroblastoma in Morocco. Journal of Global Oncology. 2(3_suppl). 80s–81s. 5 indexed citations
18.
Brown, Jennifer R., Jacqueline C. Barrientos, Paul M. Barr, et al.. (2013). Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study. Blood. 122(21). 525–525. 40 indexed citations
19.
Bagnato, Francesca, Zeena Salman, Robert L Kane, et al.. (2010). T 1 cortical hypointensities and their association with cognitive disability in multiple sclerosis. Multiple Sclerosis Journal. 16(10). 1203–1212. 20 indexed citations
20.
Salman, Zeena, Gregory D. Kirk, & Mark D. DeBoer. (2010). High Rate of Obesity-Associated Hypertension among Primary Schoolchildren in Sudan. International Journal of Hypertension. 2011. 1–5. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anca Prica Breakdown of academic impact, for papers by Thomas E. Lew Breakdown of academic impact, for papers by Tzung‐Chih Tang Breakdown of academic impact, for papers by Randy Davis Breakdown of academic impact, for papers by Ilaria Nichele Breakdown of academic impact, for papers by Marwan Yared Breakdown of academic impact, for papers by Peter Joosten Breakdown of academic impact, for papers by Vittorio Meneghini Breakdown of academic impact, for papers by S Gentili Breakdown of academic impact, for papers by Frank T. Ward
Rankless by CCL
2026